reports
Washington H. Soul Pattinson & Company Limited: 1 director
A director at Washington H. Soul Pattinson & Company Limited bought 15,034 shares at 33.310AUD and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
Aboitiz Equity Ventures Inc: 2 directors
Two Directors at Aboitiz Equity Ventures Inc bought 1,896,400 shares at between 38.974PHP and 39.438PHP. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
Global Top E-Commerce Co Ltd: 1 director
A director at Global Top E-Commerce Co Ltd sold 1,756,700 shares at 2.240CNY and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Shinhan Financial Group Co Ltd: 4 directors
A director at Shinhan Financial Group Co Ltd bought 500 shares at 40,550.000KRW and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
- ABGSC Pulp & Paper Research
- Ali Shemmari
- Nikola Kalanoski
Sodexo - Financial report for First half Fiscal 2024 available
Sodexo - Financial report for First half Fiscal 2024 available Regulated information Issy-les-Moulineaux, April 19, 2024 Financial Report for First half Fiscal 2024 available Sodexo announces that its First half Fiscal 2024 Financial report is available online and filed with the Autorité des marchés financiers (AMF). This document is available on Sodexo’s website, , under “Regulated information” in the ”Investors section”. It includes the condensed consolidated financial statements for First half Fiscal 2024, the First half activity report, the statement of responsibility for the First ...
Biophytis announces ratio change under its American Depositary Receipt...
Biophytis / Key word(s): Miscellaneous Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program 19-Apr-2024 / 07:00 CET/CEST Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Paris (France) and Cambridge (Massachusetts, USA), April 19, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today annouces that it will change the ratio o...
Biophytis annonce un changement de ratio pour son programme d'American...
Biophytis / Mot-clé(s) : Autres Biophytis annonce un changement de ratio pour son programme d'American Depositary Receipt ('ADR') 19-Avr-2024 / 07:00 CET/CEST Biophytis annonce un changement de ratio pour son programme d'American Depositary Receipt ("ADR") Paris, France, Cambridge (Massachusetts, États-Unis), 19 avril 2024 – 7h00 – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), («Biophytis» ou la «Société»), une société de biotechnologie au stade clinique spécialisée dans le développement de traitements pour les maladies liées à l'âge, annonce aujourd'hui qu'elle...
Cicor Technologies Ltd. – Shareholders approve all proposals
Cicor Technologies Ltd / Key word(s): AGMEGM Cicor Technologies Ltd. – Shareholders approve all proposals 19.04.2024 / 07:00 CET/CEST Bronschhofen, April 19, 2024 – At yesterday's Annual General Meeting of Cicor Technologies Ltd. (SIX Swiss Exchange: CICN) in Zurich, the shareholders approved all proposals. The Annual General Meeting approved the 2023 annual report, the annual financial statements, the consolidated financial statements, the sustainability report and the appropriation of available earnings. It also granted discharge to the members of the Board of Directors and Group...
Cicor Technologies Ltd. – Aktionärinnen und Aktionäre genehmigen alle ...
Cicor Technologies Ltd / Schlagwort(e): Generalversammlung Cicor Technologies Ltd. – Aktionärinnen und Aktionäre genehmigen alle Anträge 19.04.2024 / 07:00 CET/CEST Bronschhofen, 19. April 2024 – An der gestrigen ordentlichen Generalversammlung der Cicor Technologies Ltd. (SIX Swiss Exchange: CICN) in Zürich haben die Aktionärinnen und Aktionäre allen Anträgen zugestimmt. Die Generalversammlung genehmigte den Jahresbericht 2023, die Jahresrechnung, die Konzernrechnung, den Nachhaltigkeitsbericht sowie die Verwendung des Bilanzergebnisses und erteilte den Mitgliedern des Verwaltungs...
- ABGSC Capital Goods Research
- Karl Bokvist
u-blox shareholders approve all motions proposed by the Board of Direc...
u-blox AG / Key word(s): AGMEGM u-blox shareholders approve all motions proposed by the Board of Directors at the Ordinary General Meeting 2024 19.04.2024 / 07:00 CET/CEST Thalwil, Switzerland – 19 April 2024 – u-blox (SIX: UBXN), a global provider of leading positioning and wireless communication technologies and services, announces that shareholders approved all motions proposed by the Board of Directors at today’s Ordinary Annual General Meeting 2024, held in Horgen. Shareholders re-elected André Müller as Chairman of the Board of Directors. Ulrich Looser, Markus Borchert, Kari...
Addex to Present at the Swiss Biotech Day 2024
Addex to Present at the Swiss Biotech Day 2024 Geneva, Switzerland, April 19, 2024 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland. In his live presentation, scheduled for 13:45 – 14:00 CEST, on April 23, 2024, in the Samarkand room on the third floor, Mr. Dyer will provide a corporate update and discuss recent developments at Addex. Mr. Dyer will be available fo...
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line ...
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq®1) in patients with HP...
Nyrstar NV 2023 Full Year Results
Nyrstar NV 2023 Full Year Results Regulated Information Nyrstar NV 2023 Full Year Results 19 April 2024 at 07:00 CEST Nyrstar NV ("Nyrstar" or the “Company”) is today announcing the publication of its financial statements for the twelve months ended 31 December 2023 (“Full Year Results 2023”). The Full Year Results 2023 have been prepared on a discontinuity basis as a result of the decision of the extraordinary shareholders’ meeting of 9 December 2019 to reject the continuation of the Company’s activities. The Company has received from its auditor, and is publishing toda...
Nyrstar NV Jaarresultaten 2023
Nyrstar NV Jaarresultaten 2023 Gereglementeerde Informatie Nyrstar NV Jaarresultaten 2023 19 april 2024 om 07.00 CEST Nyrstar NV ("Nyrstar" of de “Vennootschap”) kondigt vandaag de publicatie van haar jaarrekening aan voor de twaalf maanden afgesloten op 31 december 2023 (“Jaarresultaten 2023”). De Jaarresultaten 2023 werden opgesteld op basis van discontinuïteit als gevolg van de beslissing van de buitengewone algemene vergadering van 9 december 2019 om de voortzetting van de activiteiten van de Vennootschap te verwerpen. De Vennootschap heeft van haar commissaris een co...
- Marc Hesselink
- CFA
- Thymen Rundberg
CM.com/On track/BUY
CM.com's 1Q24 update was largely inline with our expectations with lower gross profit compensated by better OPEX control. We expect this trend to continue and as a result we have limited changes to EBITDA estimates. We believe the company is well on track to become structurally profitable on a FCF basis from 2H24 onwards. This should mitigate any balance sheet uncertainty. We keep our BUY rating and €10.50 target price.
- Roelof-Jan van den Akker
FX Technical/Essential currency/FX pairs
In the beginning of this year, we mentioned that a longer-term consolidation in the US Dollar seems most likely, not showing a clear direction for this year. Possibly some interesting rallies and declines from time to time which will offer a trading opportunity.
Construction contract in Latvia (solar panel power plant in Vārme pari...
Construction contract in Latvia (solar panel power plant in Vārme parish) On 18 April 2024, PS MB.MEE, part of AS Merko Ehitus group, and SIA SP Venta, which sole shareholder and financier of the project development is UAB Ignitis renewables, entered into a contract to for the construction of solar panel power plant located in Vārme parish, Kuldīga district, Latvia.The works include installation of solar panels with total capacity of 93.5 MW DC, 18 medium-voltage power stations, 232 combiner boxes, irradiance sensors, weather stations, construction of access roads, drainage systems, constru...
- Quirijn Mulder
Vopak/FY24 guidance too cautious/BUY
When Vopak reports its 1Q24 next week, we foresee a positive surprise in the numbers. The main reason in our view is that the guidance given by management is too cautious, followed suit by consensus estimates. In our view market conditions haven't changed overnight like volatile oil markets due to geopolitical unrest, stable chemical markets and higher results for gas thanks to Eemshaven contribution. With this outlook, good cash flow in FY24 and in the years ahead, thanks to dedicated managemen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.